SATIVEX AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL

Trial Profile

SATIVEX AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Muscle spasticity
  • Focus Therapeutic Use
  • Acronyms SAVANT
  • Sponsors Almirall Hermal GmbH
  • Most Recent Events

    • 28 Oct 2017 Primary endpoint (30% NRS spasticity improvement) has been met, as per results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 28 Oct 2017 Results assessing efficacy presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 23 Jun 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top